WuXi AppTec Co. Ltd Asset Resilience Ratio

Latest as of March 2026: 6.96%

WuXi AppTec Co. Ltd asset resilience ratio. WuXi AppTec Co. Ltd (WX8) has an Asset Resilience Ratio of 6.96% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See WuXi AppTec Co. Ltd defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.

Liquid Assets

€7.48 Billion
≈ $8.74 Billion USD Cash + Short-term Investments

Total Assets

€107.41 Billion
≈ $125.58 Billion USD All company assets

Resilience Assessment

Low
Financial Resilience Level

Asset Resilience Ratio of WuXi AppTec Co. Ltd (2016–2025)

Asset resilience ratio of WuXi AppTec Co. Ltd from 2016 to 2025. This chart shows how WuXi AppTec Co. Ltd's Asset Resilience Ratio has changed over time. Read WX8 total liabilities for a breakdown of total debt and financial obligations.

Liquid Assets Composition Over Time

This chart breaks down WuXi AppTec Co. Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see WX8 total assets.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents €0.00 0%
Short-term Investments €7.48 Billion 6.96%
Total Liquid Assets €7.48 Billion 6.96%

Asset Resilience Insights

  • Limited Liquidity: WuXi AppTec Co. Ltd maintains only 6.96% of assets in liquid form.
  • This low level may indicate efficient asset utilization but could pose risks during economic downturns.
  • The company has significant short-term investments, indicating active treasury management.

WuXi AppTec Co. Ltd Industry Peers by Asset Resilience Ratio

Compare WuXi AppTec Co. Ltd's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Revvity Inc.
NYSE:RVTY
Diagnostics & Research 0.00%
Diagnósticos da América S.A
SA:DASA3
Diagnostics & Research 10.42%
SMO ClinPlus Co. Ltd.
SHE:301257
Diagnostics & Research 15.78%
Monash Ivf Group Ltd
AU:MVF
Diagnostics & Research 1.60%
RHYTHM Biosciences Ltd
AU:RHY
Diagnostics & Research 2.74%
Bcal Diagnostics Ltd
AU:BDX
Diagnostics & Research 0.00%
Sonic Healthcare Ltd
AU:SHL
Diagnostics & Research 0.13%
Integral Diagnostics Ltd
AU:IDX
Diagnostics & Research 0.03%

WuXi AppTec Co. Ltd Asset Resilience Ratio by Year (2016–2025)

WuXi AppTec Co. Ltd asset resilience ratio by year from 2016 to 2025. The table below shows the annual Asset Resilience Ratio data for WuXi AppTec Co. Ltd.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 5.63% €5.81 Billion
≈ $6.79 Billion
€103.12 Billion
≈ $120.56 Billion
+4.09pp
2024-12-31 1.54% €1.23 Billion
≈ $1.44 Billion
€80.33 Billion
≈ $93.91 Billion
+1.52pp
2023-12-31 0.01% €11.00 Million
≈ $12.86 Million
€73.67 Billion
≈ $86.13 Billion
+0.01pp
2022-12-31 0.00% €2.00 Million
≈ $2.34 Million
€64.69 Billion
≈ $75.63 Billion
-0.95pp
2021-12-31 0.96% €527.29 Million
≈ $616.46 Million
€55.13 Billion
≈ $64.45 Billion
-9.02pp
2020-12-31 9.98% €4.62 Billion
≈ $5.40 Billion
€46.29 Billion
≈ $54.12 Billion
+4.16pp
2019-12-31 5.82% €1.70 Billion
≈ $1.99 Billion
€29.24 Billion
≈ $34.18 Billion
-3.56pp
2018-12-31 9.38% €2.13 Billion
≈ $2.48 Billion
€22.67 Billion
≈ $26.50 Billion
+9.26pp
2017-12-31 0.12% €14.74 Million
≈ $17.23 Million
€12.58 Billion
≈ $14.71 Billion
-3.98pp
2016-12-31 4.10% €434.19 Million
≈ $507.61 Million
€10.59 Billion
≈ $12.38 Billion
--
pp = percentage points

About WuXi AppTec Co. Ltd

F:WX8 Germany Diagnostics & Research
Market Cap
$11.75 Billion
€10.05 Billion EUR
Market Cap Rank
#1935 Global
#413 in Germany
Share Price
€19.69
Change (1 day)
-2.38%
52-Week Range
€10.60 - €25.00
All Time High
€25.00
About

WuXi AppTec Co., Ltd., an investment holding company, provides research and manufacturing services to discover, develop, and manufacture spectrum for small molecule drugs in the People's Republic of China, the United States, Europe, and internationally. The company operates through WuXi Chemistry, WuXi Testing, WuXi Biology, and Others segments. It offers contract research, development, and manuf… Read more